Strong neuropathological, genetic, and clinical evidence implicates tau protein abnormalities as having a central role in tauopathies and thus, there is a great interest in the development of tau-directed therapeutics. Boyd Ghosh, MBBS, PhD, University Hospital Southampton, Southampton, UK, shares his thoughts on the future of tauopathy treatment, including the potential of isoform-specific agents and combination strategies. This interview took place at The BNA 2023 International Festival of Neuroscience in Brighton, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Boyd Ghosh reports the following disclosures:
President of the BNPA (British Neuropsychiatric Association)
Trustee and research committee member PSP Association
Lectured for UCB and GSK on atypical Parkinsonism
Advisory board for NICE, UCB and Biogen
Drug trials for Biogen, Takeda, UCB, Pfizer, TauRx, Novartis and Laboratoire Français de Fractionnement et de Biotechnologies